Corcept Therapeutics | CORT - Current Liabilities


Corcept Therapeutics reported $149.18M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Alaunos Therapeutics USD 595K 218K Mar/2026
ANI Pharmaceuticals USD 239.51M 38.6M Mar/2026
Ardelyx USD 109.57M 20.96M Mar/2026
Aurora Cannabis CAD 145.94M 21.82M Dec/2025
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Canopy Growth CAD 98.29M 17.19M Dec/2025
Corcept Therapeutics USD 149.18M 16.9M Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Esperion Therapeutics USD 300.36M 451K Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Knight Therapeutics CAD 165.26M 12.58M Dec/2025
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Novartis USD 31.37B 4.1B Mar/2026
Novartis USD 27.28B 4.72B Dec/2025
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 108.79M 11.8M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Supernus Pharmaceuticals USD 373.93M 35.76M Mar/2026
TG Therapeutics USD 187.11M 33.35M Mar/2026